Fundz

Who to call at Sagimet, and when

Fundz watches for the moments Sagimet starts buying, and tells you who to reach.

  • An alert the day Sagimet raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Sagimet, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Sagimet. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Sagimet Biosciences Enters Licensing Agreement with TAPI

Dec 17, 2025

Contract Type

licensing

San MateoBiotechnologyHealth CarePharmaceuticalBiopharma

Description

On December 17, 2025, Sagimet Biosciences Inc. announced its entry into a license agreement with Assia Chemical Industries Ltd. Under this agreement, TAPI has granted Sagimet a global, exclusive license for certain intellectual property rights related to innovative forms of resmetirom API. This allows Sagimet to evaluate and potentially develop a fixed-dose combination product containing denifanstat and resmetirom.

Company Information

Company

Sagimet

Location

San Mateo, California, United States

About

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet.com.

Related People

Thierry
Likely contact at this company
••••••••@••••••••

See Thierry's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Sagimet's next move

Learn about Strategic plan

Sagimet signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.